Back to Journals » Veterinary Medicine: Research and Reports » Volume 10

First identification of mcr-1/mcr-2 genes in the fecal microbiota of Canadian commercial pigs during the growing and finishing period

Authors Rhouma M , Thériault W, Rabhi N , Duchaine C , Quessy S, Fravalo P

Received 21 January 2019

Accepted for publication 14 May 2019

Published 4 July 2019 Volume 2019:10 Pages 65—67

DOI https://doi.org/10.2147/VMRR.S202331

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Young Lyoo



Mohamed Rhouma,1 William Thériault,1 Nassima Rabhi,1 Caroline Duchaine,2 Sylvain Quessy,1 Philippe Fravalo1

1Department of Pathology and Microbiology, Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC J2S 2M2, Canada; 2Department of Biochemistry, Microbiology and Bioinformatics, Faculty of Science and Engineering, Université Laval, Québec, QC G1V 4G5, Canada

Colistin is considered one of the last-resort antibiotics used for the treatment of infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) in humans.1 This antibiotic is classified by the World Health Organization, among the category of the Highest Priority Critically Important Antimicrobials for human medicine.2 In this regard, the global dissemination of plasmid-mediated colistin resistance, conferred by themobile colistin resistance (mcr) genes, has raised serious concern among physicians and scientists worldwide.2 On the other hand, colistin has been widely used in food animals in many countries either for disease therapy, prophylaxis or for growth promotion.3 Many studies reported a high prevalence of mcr genes on bacterial isolates from animals' origin compared to humans, and consequently animals, particularly pig production, were pointed out as the greatest cause of bacterial colistin resistance spread.1 In pigs, mcr genes were isolated mainly from colistin resistant E. coli, Salmonella and Klebsiella isolates, with mcr-1 gene being themost frequently identified gene among the eight types of mcr genes currently described.1 Among other Gram-negative bacteria (GNB) of pig origin, mcr genes were identified in Moraxella spp.,4 and in Aeromonas hydrophila,enforcing the interest to consider the mcr presence at the microbiota level. In Canada, although colistin is not approved for use in veterinarymedicine, it was sometimes used in pigs according to special precautions for the oral treatment of digestive infections caused by GNB.1 Nevertheless, mcr-1 gene has been identified in E. coli isolated from humans, as well as from lean ground beef in Canada.6 However, to the best of our knowledge, mcr genes have never been identified in animals at the farm level in Canada. Here we report he screening of fecal samples obtained from one Canadian commercial pig farm, to determine the prevalence over the growing period of mcr-1 and mcr-2 genes in the fecal microbiota of pigs. Colistin has never been used in this farm. However, tiamulin and chlortetracycline were used in the post-weaning period and salinomycin as well as narasin were used during the growing phase.

Colistin is considered one of the last-resort antibiotics used for the treatment of infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) in humans.1 This antibiotic is classified by the World Health Organization, among the category of the Highest Priority Critically Important Antimicrobials for human medicine.2 In this regard, the global dissemination of plasmid-mediated colistin resistance, conferred by the mobile colistin resistance (mcr) genes, has raised serious concern among physicians and scientists worldwide.2 On the other hand, colistin has been widely used in food animals in many countries either for disease therapy, prophylaxis or for growth promotion.3 Many studies reported a high prevalence of mcr genes on bacterial isolates from animals' origin compared to humans, and consequently animals, particularly pig production, were pointed out as the greatest cause of bacterial colistin resistance spread.1 In pigs, mcr genes were isolated mainly from colistin resistant E. coli, Salmonella and Klebsiella isolates, with mcr-1 gene being the most frequently identified gene among the eight types of mcr genes currently described.1 Among other Gram-negative bacteria (GNB) of pig origin, mcr genes were identified in Moraxella spp.,4 and in Aeromonas hydrophila,5 enforcing the interest to consider the mcr presence at the microbiota level. In Canada, although colistin is not approved for use in veterinary medicine, it was sometimes used in pigs according to special precautions for the oral treatment of digestive infections caused by GNB.1 Nevertheless, mcr-1 gene has been identified in E. coli isolated from humans, as well as from lean ground beef in Canada.6 However, to the best of our knowledge, mcr genes have never been identified in animals at the farm level in Canada. Here we report the screening of fecal samples obtained from one Canadian commercial pig farm, to determine the prevalence over the growing period of mcr-1 and mcr-2 genes in the fecal microbiota of pigs. Colistin has never been used in this farm. However, tiamulin and chlortetracycline were used in the post-weaning period and salinomycin as well as narasin were used during the growing phase. The present study was primarily designed to investigate the relationship between gut microbiota composition and some welfare problems in pigs (e.g., tail biting). Fecal samples have been collected between January 2017 and April 2017, from one commercial pig farm located in the province of Quebec (Canada). Pigs were sampled 5 times during the study period. In fact, fresh fecal material was collected directly from each animal’s rectum using disposable gloves, and immediately 1 g of each sample was placed in liquid nitrogen. At the laboratory, these samples were stored at −80ºC until DNA extraction. In the current study, fecal samples that have been obtained from 62, 60, 62, 33, and 44 pigs, which correspond to the sampling time; I, II, III, IV and V respectively (Table 1), were used to identify mcr-1 and mcr-2 genes. Total genomic DNA was extracted using a standard Phenol-Chloroform method. All DNA extracts were screened by PCR for the presence of mcr-1 and mcr-2 genes, using primers and conditions as previously described.7 Positive samples for mcr (12) genes were confirmed by the Sanger sequencing of the amplified fragment. The mcr-1 gene has been identified in all sampling dates. However, mcr-2 gene was detected in three of the five sampling dates (Table 1). Only one animal harbor in its fecal microbiota both mcr-1 gene and mcr-2 gene, however this finding was transitory, since this result was observed only at the first sampling time. It is noteworthy that 11.4% of pigs were sent to the slaughterhouse with mcr-1 gene in their microbiota, which could represent a threat for consumers in terms of colistin-resistance genes transfer. Our results corroborate the study of Meinersmann et al who reported the identification of mcr-1 gene in the cecal contents of pigs in the United States, even in the absence of evidence of colistin use in pigs in this country.8 However, the Canadian Integrated Program for Antimicrobial Resistance Surveillance targets only the antimicrobial resistance profile of E. coli and Salmonella at pig farms, which can explain in part why the mcr genes have never been identified at the farm level in Canada. Our results highlight the need to expand monitoring mcr genes and colistin resistance to other Enterobacteriaceae species than those routinely analyzed. In our study, the bacterial genus harboring the mcr-1 and/or the mcr-2 genes was not identified. However, we unequivocally confirm the presence of these genes in the microbiota of pigs in a conventional facility. It should be stressed here that mcr-1 and mcr-2 genes have been identified in the fecal microbiota of pigs that have never been treated with colistin. Such presence could be related to the possible contamination of feed by bacteria harboring these genes. In fact, mcr-1 gene has already been isolated from colistin-resistant E. coli recovered form animal feed.9 On the other hand, mcr-1 gene was identified in 60% of air samples from finishing swine barns in Canada.10 Thereby, swine confinement buildings could be also a source of contamination for pigs. Moreover, based on known co-localization of mcr genes with other antimicrobial genes within the same mobile genetic elements, selective pressure imposed by other antimicrobials could favor the selection of mcr genes, even in the absence of colistin use. Indeed, it was reported that a colistin-resistant E. coli strain derived from animal origin harbored on the same plasmid, in addition to mcr-1 gene, several resistance-encoding genes such as; trimethoprim (dfrA1), tetracycline (tetA), aminoglycoside (aadA1, aph(6)-Id or strA, and aph(3″)-Ib/strB), and sulphonamide (sul1) antibiotics.11 In our study, the use of chlortetracycline could be associated with a selective pressure on mcr genes. However, to the best of our knowledge, neither cross-resistance between colistin and coccidiostat ionophore drugs (e.g., salinomycin, narasin), nor between colistin and tiamulin has been reported in the scientific literature.

Table 1 Detection of mcr-1 and mcr-2 genes in the fecal microbiota in a Canadian commercial pigs farm during the growing and finishing period, 2017

Further studies are needed to determine the role of the selection pressure by other antimicrobials as well as pig’s environment and feed in the dissemination of colistin resistance genes in pigs.

Acknowledgments

This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) (520873-17).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Rhouma M, Beaudry F, Theriault W, Letellier A. Colistin in pig production: chemistry, mechanism of antibacterial action, microbial resistance emergence, and one health perspectives. Front Microbiol. 2016;7:1–22. doi:10.3389/fmicb.2016.01789

2. Rhouma M, Beaudry F, Letellier A. Resistance to colistin: what is the fate for this antibiotic in pig production? Int J Antimicrob Agents. 2016;48(2):119–126. doi:10.1016/j.ijantimicag.2016.04.008

3. Kempf I, Jouy E, Chauvin C. Colistin use and colistin resistance in bacteria from animals. Int J Antimicrob Agents. 2016;48(6):598–606. doi:10.1016/j.ijantimicag.2016.09.016

4. AbuOun M, Stubberfield EJ, Duggett NA, et al. mcr-1 and mcr-2 (mcr-6.1) variant genes identified in Moraxella species isolated from pigs in Great Britain from 2014 to 2015. J Antimicrob Chemother. 2018;73(10):2904. doi:10.1093/jac/dky272

5. Ma S, Sun C, Hulth A, et al. Mobile colistin resistance gene mcr-5 in porcine Aeromonas hydrophila. J Antimicrob Chemother. 2018;73(7):1777–1780. doi:10.1093/jac/dky110

6. Mulvey MR, Mataseje LF, Robertson J, et al. Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis. 2016;16(3):289–290. doi:10.1016/S1473-3099(16)00067-0

7. Rhouma M, Bessalah S, Salhi I, Theriault W, Fairbrother JM, Fravalo P. Screening for fecal presence of colistin-resistant Escherichia coli and mcr-1 and mcr-2 genes in camel-calves in southern Tunisia. Acta Vet Scand. 2018;60(1):35. doi:10.1186/s13028-018-0389-1

8. Meinersmann RJ, Ladely SR, Plumblee JR, Cook KL, Thacker E. Prevalence of mcr-1 in the cecal contents of food animals in the United States. Antimicrob Agents Chemother. 2017;61(2). doi:10.1128/AAC.02244-16

9. Yu CY, Ang GY, Chin PS, Ngeow YF, Yin WF, Chan KG. Emergence of mcr-1-mediated colistin resistance in Escherichia coli in Malaysia. Int J Antimicrob Agents. 2016;47(6):504–505. doi:10.1016/j.ijantimicag.2016.04.004

10. Pilote J, Létourneau V, Girard M, Duchaine C. Quantification of airborne dust, endotoxins, human pathogens and antibiotic and metal resistance genes in Eastern Canadian swine confinement buildings. Aerobiologia. 2019;35(2):283–296. doi:10.1007/s10453-019-09562-6

11. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Butaye P, Goossens H. Colistin resistance gene mcr-1 harboured on a multidrug resistant plasmid. Lancet Infect Dis. 2016;16(3):283–284. doi:10.1016/S1473-3099(16)00012-8

Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.